Dual-site magnetic stimulation is being paired with exercise to target Parkinson’s balance failure
A new randomized trial in China is testing whether sensorimotor cortical paired associative magnetic stimulation can sharpen the effect of exercise in people with Parkinson’s disease who struggle with balance and gait. The protocol is built around a simple clinical problem: conventional rehabilitation can help, but motor training alone often leaves the sensory and network-level contributors to postural instability insufficiently addressed.
The study is designed as a three-arm, double-blind, randomized controlled trial enrolling 72 participants. One group will receive sensorimotor cortical paired associative stimulation, or sm-PAS, followed by exercise; a second group will receive single-site motor cortex stimulation followed by exercise; and a third will receive sham stimulation followed by exercise. All three groups will complete the same 2-week intervention schedule, with five sessions each week.
Balance impairment in Parkinson’s disease is not only a matter of weak movement output. It also reflects impaired integration of sensory information, altered cortical excitability, and reduced coordination across motor networks. By attempting to engage both the supplementary motor area and the temporoparietal junction, the trial moves beyond a narrow motor-cortex-only approach and into the circuitry that supports anticipatory postural control and multisensory integration.
Why the protocol targets more than the motor cortex
The trial’s logic follows from the biology of Parkinsonian gait and postural dysfunction. The motor cortex is a reasonable stimulation target, but the symptoms being treated do not arise from the motor cortex alone. Patients with Parkinson’s disease often walk with shortened stride length, slower pace, and unstable postural responses because the nervous system has trouble combining proprioceptive, vestibular, and visual signals into a coherent motor plan.
In that context, a paired associative protocol offers a more network-oriented strategy. sm-PAS delivers paired stimuli to the supplementary motor area and the temporoparietal junction using an individualized interstimulus interval. The timing element matters because paired associative stimulation is intended to harness timing-dependent plasticity, a mechanism that may alter how cortical regions communicate with one another during movement planning and balance reactions.
The comparison with single-site motor cortex stimulation is equally important. If the dual-site protocol outperforms the motor cortex-only arm, the result would suggest that distributed sensorimotor modulation adds value beyond a conventional focal approach. If both active arms behave similarly, the simpler protocol may prove sufficient. Either way, the trial is set up to answer a clinically practical question about how to structure pre-exercise neuromodulation in a disorder where falls and gait decline carry heavy functional consequences.
Primary endpoint centers on balance and gait performance
The primary outcome is the Mini-Balance Evaluation Systems Test, a clinically familiar measure of balance and gait. Investigators will compare the change in Mini-BESTest scores from baseline to Week 2 between the sm-PAS group and both control arms. That endpoint fits the symptom burden being addressed. Balance failure in Parkinson’s disease often declares itself at the bedside long before more dramatic events such as falls, and a validated performance measure can capture whether the intervention shifts real-world mobility rather than only laboratory physiology.
Assessments will occur at baseline, after 1 week, after 2 weeks, and again at 1 month follow-up. The repeated measurement schedule gives the protocol room to detect early physiologic change and whether any improvement persists beyond the treatment window. In rehabilitation studies, durability can matter as much as immediate gain, because transient changes in excitability do not necessarily translate into a sustained difference in daily walking or postural control.
A single sentence captures the clinical stakes: this trial is trying to determine whether a short course of network-targeted stimulation can improve balance before the gains fade.
Secondary measures extend from symptoms to physiology
The secondary outcome set is broader than gait alone. Motor symptoms and quality of life will be tracked, which is appropriate for a disorder in which modest changes in balance can still influence independence, confidence, and activity levels. The mechanistic program is even more ambitious. Cortical excitability will be measured with paired-pulse TMS, while cortical activation will be assessed with functional near-infrared spectroscopy.
Those measures give the protocol a translational edge. Paired-pulse TMS can probe inhibitory and facilitatory circuits, offering a window into how stimulation changes local cortical responsiveness. Functional near-infrared spectroscopy adds a hemodynamic view of cortical engagement during task-related activity. Together, the methods may help explain whether any behavioral improvement is accompanied by a measurable shift in sensorimotor network function.
Mechanistic testing is not a decorative extra here. In Parkinson’s disease, the same patient can show poor gait because of impaired automaticity, altered sensory weighting, and defective cortical preparation for movement. If sm-PAS changes both physiology and performance, the trial may help link a specific stimulation pattern to a specific rehabilitation response. If physiology changes without a clear clinical gain, the study will still clarify the gap between cortical modulation and meaningful mobility benefit.
Trial design, ethics, and analytic plan are tightly defined
The study uses a double-blind design, which is essential when placebo effects and expectation can influence rehabilitation outcomes. Participants, investigators, and treatment allocation procedures are structured to reduce bias across the three arms. The primary estimate is the between-group difference in the change of Mini-BESTest scores from baseline to Week 2, comparing sm-PAS with both sham stimulation and single-site motor cortex stimulation.
Statistical analysis will rely on linear mixed-effects models under an intention-to-treat principle. That choice is appropriate for a repeated-measures trial with multiple time points, because it can incorporate all available observations while handling within-subject correlation over time. It also aligns with the clinical reality of Parkinson’s disease studies, where symptom fluctuation and incomplete follow-up can complicate simple before-and-after comparisons.
Ethics approval has been obtained from the Biomedical Ethics Committee of West China Hospital, Sichuan University, and the trial is registered as ChiCTR2600116787. Findings are planned for peer-reviewed publication.
This is a protocol, not a results paper, so the major question remains unanswered: whether dual-site sensorimotor stimulation can move the Mini-BESTest enough to matter in daily movement. The answer will depend not only on whether the active arm outperforms sham, but also on whether it offers an advantage over a more conventional motor cortex protocol, a distinction that will determine whether the added complexity is worth carrying into rehabilitation practice.